AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aprea Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference.
ByAinvest
Thursday, Aug 28, 2025 8:41 am ET1min read
Aprea Therapeutics, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 3:30 PM ET. The presentation will be webcasted and available for 90 days on the company's Investors page. Aprea's mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones.
Doylestown, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel in New York. A webcast of the presentation will be accessible for 90 days through the company's investor relations website.The presentation will provide an update on Aprea's mission to develop novel cancer therapies that target cancer cells directly while minimizing harm to healthy cells. This approach aims to eradicate tumors while reducing the risk of toxicity associated with conventional chemotherapy and other treatments. Aprea's lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications.
Aprea's investor relations website will serve as a platform for disclosing material nonpublic information and complying with Regulation FD disclosure obligations. The webcast link will be available on the Aprea Investors page under "News & Events" for 90 days.
About Aprea Therapeutics, Inc.
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells. The company's mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
References:
[1] https://www.globenewswire.com/news-release/2025/08/28/3140794/0/en/Aprea-Therapeutics-to-Present-at-H-C-Wainwright-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/APRE/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-yqnrncqbl43d.html
[3] https://www.stocktitan.net/news/APRE/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet